Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

dimethyl glutamate

Biogen Idec building

NICE green light for Biogen’s oral MS drug

Overturns previous negative guidance for Tecfidera

Free Thinking: Biosimilars: Friend or foe to healthcare?

Our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.

Research Partnership

- PMLiVE

Biosimilar Lantus leads CHMP opinions

Boehringer and Lilly’s insulin one of six new medicines recommended for EU approval

- PMLiVE

Merck KGaA drops Ono-partnered multiple sclerosis drug

Decides phase III candidate ceralifimod isn't worth its continued investment

- PMLiVE

ADA: Lilly/Boehringer insulin glargine matches Lantus

Biosimilar demonstrates equal efficacy to Sanofi’s big-selling diabetes treatment

- PMLiVE

Creating a brand identity for biosimilars

How to ensure a replicated biologic is seen as more than just a tribute brand

National Institute for Health and Care Excellence NICE logo

NICE backs reimbursement of Sanofi’s MS drug Lemtrada

Final guidance opens doors for use on NHS in England and Wales

- PMLiVE

CHMP backs European approval for six new medicines

Recommends drugs by PTC Therapeutics, Roche, Biogen Idec, Octapharma, Alcon and Veloxis Pharma

- PMLiVE

Teva backs laquinimod for MS despite CHMP rejection

EMA confirms negative opinion after re-examination

- PMLiVE

FDA unveils new biosimilars guidance

Will clarify route to market for copies of biological drugs

- PMLiVE

Following the biologic path

Biosimilar regulations in Canada, the US and Europe all have a degree of uncertainty

- PMLiVE

New Novartis MS app will turn up the heat on its rivals

Patients can use SymTrac iPhone app to track symptoms and relapses on their current treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links